Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma

Hsin-An Chen, Tsang Chih Kuo, Chi Feng Tseng, Jui Ti Ma, Shu Ting Yang, Chia Jui Yen, Ching Yao Yang, Shian-Ying Sung, Jen Liang Su

研究成果: 雜誌貢獻文章

31 引文 (Scopus)

摘要

Angiopoietin-like protein 1 (ANGPTL1) has been shown to act as a tumor suppressor by inhibiting angiogenesis, cancer invasion, and metastasis. However, little is known about the effects of ANGPTL1 on sorafenib resistance and cancer stem cell properties in hepatocellular carcinoma (HCC) and the mechanism underlying these effects. Here, we show that ANGPTL1 expression positively correlates with sorafenib sensitivity in HCC cells and human HCC tissues. ANGPTL1 significantly decreases epithelial-mesenchymal transition (EMT)-driven sorafenib resistance, cancer stemness, and tumor growth of HCC cells by repressing Slug expression. ANGPTL1 directly interacts with and inactivates MET receptor, which contributes to Slug suppression through inhibition of the extracellular receptor kinase/protein kinase B (ERK/AKT)-dependent early growth response protein 1 (Egr-1) pathway. ANGPTL1 expression inversely correlates with Slug expression, poor sorafenib responsiveness, and poor clinical outcomes in HCC patients. Conclusion: ANGPTL1 inhibits sorafenib resistance and cancer stemness in HCC cells by repressing EMT through inhibition of the MET receptor−AKT/ERK−Egr-1−Slug signaling cascade. ANGPTL1 may serve as a novel MET receptor inhibitor for advanced HCC therapy. (Hepatology 2016;64:1637-1651).
原文英語
頁(從 - 到)1637-1651
頁數15
期刊Hepatology
64
發行號5
DOIs
出版狀態已發佈 - 十一月 1 2016

指紋

Angiopoietins
Hepatocellular Carcinoma
Gastropoda
Neoplasms
Proteins
Epithelial-Mesenchymal Transition
Early Growth Response Protein 1
Proto-Oncogene Proteins c-akt
Neoplastic Stem Cells
sorafenib
Gastroenterology
Phosphotransferases
Neoplasm Metastasis

ASJC Scopus subject areas

  • Hepatology

引用此文

Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma. / Chen, Hsin-An; Kuo, Tsang Chih; Tseng, Chi Feng; Ma, Jui Ti; Yang, Shu Ting; Yen, Chia Jui; Yang, Ching Yao; Sung, Shian-Ying; Su, Jen Liang.

於: Hepatology, 卷 64, 編號 5, 01.11.2016, p. 1637-1651.

研究成果: 雜誌貢獻文章

Chen, Hsin-An ; Kuo, Tsang Chih ; Tseng, Chi Feng ; Ma, Jui Ti ; Yang, Shu Ting ; Yen, Chia Jui ; Yang, Ching Yao ; Sung, Shian-Ying ; Su, Jen Liang. / Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma. 於: Hepatology. 2016 ; 卷 64, 編號 5. 頁 1637-1651.
@article{cfe359907f004f55a949b2603f064a17,
title = "Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma",
abstract = "Angiopoietin-like protein 1 (ANGPTL1) has been shown to act as a tumor suppressor by inhibiting angiogenesis, cancer invasion, and metastasis. However, little is known about the effects of ANGPTL1 on sorafenib resistance and cancer stem cell properties in hepatocellular carcinoma (HCC) and the mechanism underlying these effects. Here, we show that ANGPTL1 expression positively correlates with sorafenib sensitivity in HCC cells and human HCC tissues. ANGPTL1 significantly decreases epithelial-mesenchymal transition (EMT)-driven sorafenib resistance, cancer stemness, and tumor growth of HCC cells by repressing Slug expression. ANGPTL1 directly interacts with and inactivates MET receptor, which contributes to Slug suppression through inhibition of the extracellular receptor kinase/protein kinase B (ERK/AKT)-dependent early growth response protein 1 (Egr-1) pathway. ANGPTL1 expression inversely correlates with Slug expression, poor sorafenib responsiveness, and poor clinical outcomes in HCC patients. Conclusion: ANGPTL1 inhibits sorafenib resistance and cancer stemness in HCC cells by repressing EMT through inhibition of the MET receptor−AKT/ERK−Egr-1−Slug signaling cascade. ANGPTL1 may serve as a novel MET receptor inhibitor for advanced HCC therapy. (Hepatology 2016;64:1637-1651).",
author = "Hsin-An Chen and Kuo, {Tsang Chih} and Tseng, {Chi Feng} and Ma, {Jui Ti} and Yang, {Shu Ting} and Yen, {Chia Jui} and Yang, {Ching Yao} and Shian-Ying Sung and Su, {Jen Liang}",
year = "2016",
month = "11",
day = "1",
doi = "10.1002/hep.28773",
language = "English",
volume = "64",
pages = "1637--1651",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma

AU - Chen, Hsin-An

AU - Kuo, Tsang Chih

AU - Tseng, Chi Feng

AU - Ma, Jui Ti

AU - Yang, Shu Ting

AU - Yen, Chia Jui

AU - Yang, Ching Yao

AU - Sung, Shian-Ying

AU - Su, Jen Liang

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Angiopoietin-like protein 1 (ANGPTL1) has been shown to act as a tumor suppressor by inhibiting angiogenesis, cancer invasion, and metastasis. However, little is known about the effects of ANGPTL1 on sorafenib resistance and cancer stem cell properties in hepatocellular carcinoma (HCC) and the mechanism underlying these effects. Here, we show that ANGPTL1 expression positively correlates with sorafenib sensitivity in HCC cells and human HCC tissues. ANGPTL1 significantly decreases epithelial-mesenchymal transition (EMT)-driven sorafenib resistance, cancer stemness, and tumor growth of HCC cells by repressing Slug expression. ANGPTL1 directly interacts with and inactivates MET receptor, which contributes to Slug suppression through inhibition of the extracellular receptor kinase/protein kinase B (ERK/AKT)-dependent early growth response protein 1 (Egr-1) pathway. ANGPTL1 expression inversely correlates with Slug expression, poor sorafenib responsiveness, and poor clinical outcomes in HCC patients. Conclusion: ANGPTL1 inhibits sorafenib resistance and cancer stemness in HCC cells by repressing EMT through inhibition of the MET receptor−AKT/ERK−Egr-1−Slug signaling cascade. ANGPTL1 may serve as a novel MET receptor inhibitor for advanced HCC therapy. (Hepatology 2016;64:1637-1651).

AB - Angiopoietin-like protein 1 (ANGPTL1) has been shown to act as a tumor suppressor by inhibiting angiogenesis, cancer invasion, and metastasis. However, little is known about the effects of ANGPTL1 on sorafenib resistance and cancer stem cell properties in hepatocellular carcinoma (HCC) and the mechanism underlying these effects. Here, we show that ANGPTL1 expression positively correlates with sorafenib sensitivity in HCC cells and human HCC tissues. ANGPTL1 significantly decreases epithelial-mesenchymal transition (EMT)-driven sorafenib resistance, cancer stemness, and tumor growth of HCC cells by repressing Slug expression. ANGPTL1 directly interacts with and inactivates MET receptor, which contributes to Slug suppression through inhibition of the extracellular receptor kinase/protein kinase B (ERK/AKT)-dependent early growth response protein 1 (Egr-1) pathway. ANGPTL1 expression inversely correlates with Slug expression, poor sorafenib responsiveness, and poor clinical outcomes in HCC patients. Conclusion: ANGPTL1 inhibits sorafenib resistance and cancer stemness in HCC cells by repressing EMT through inhibition of the MET receptor−AKT/ERK−Egr-1−Slug signaling cascade. ANGPTL1 may serve as a novel MET receptor inhibitor for advanced HCC therapy. (Hepatology 2016;64:1637-1651).

UR - http://www.scopus.com/inward/record.url?scp=84988805400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988805400&partnerID=8YFLogxK

U2 - 10.1002/hep.28773

DO - 10.1002/hep.28773

M3 - Article

C2 - 27530187

AN - SCOPUS:84988805400

VL - 64

SP - 1637

EP - 1651

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -